Treatment of asymptomatic hyperuricemia and prevention of vascular disease: A decision analytic approach

Journal of Rheumatology

Volumn 41, Issue 4, 2014, Pages 739-748

  Akkineni, Roopa ^a   Tapp, Stephanie ^b   Tosteson, Anna N A ^b   Lee, Alexandra ^c   Miller, Katherine L ^d   Choi, Hyon K ^e   Zhu, Yanyan ^e   Albert, Daniel A ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c White River Junction   (United States)

^d NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Decision analysis; Hyperuricemia

Indexed keywords

ALLOPURINOL; URATE; ANTIGOUT AGENT; URIC ACID;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEART PROTECTION; HUMAN; HYPERURICEMIA; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; SEX DIFFERENCE; TREATMENT INDICATION; UPREGULATION; URIC ACID BLOOD LEVEL; BLOOD; COMPLICATION; DECISION SUPPORT SYSTEM; FOLLOW UP; MIDDLE AGED; PROBABILITY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR DISEASES;

AGED; ALLOPURINOL; DECISION SUPPORT TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MARKOV CHAINS; MIDDLE AGED; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME; URIC ACID; VASCULAR DISEASES;

EID: 84897375086     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121231     Document Type: Article

References (41)

1. Wilcox WR, Khalaf A, Weinberger A, Kippen I, Klinenberg Jr. Solubility of uric acid and monosodium urate. Med Biol Eng 1972;10:522-31.
2. Feig DI, Mazzali M, Kang DH, Nakagawa T, Price K, Kannelis J, et al. Serum uric acid: a risk factor and a target for treatment? J Am Soc Nephrol 2006;4 Suppl 2:S69-73.
3. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63:3136-41.
4. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005;118:816-26.
5. Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology 2007;58:450-7.
6. Brand FN, McGee DL, Kannel WB, Stokes J 3rd, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 1985;121:11-8.
7. Kim SY, De Vera MA, Choi HK. Gout and mortality. Clin Exp Rheumatol 2008;5 Suppl 51:S115-9.
8. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.
9. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966;275:457-64.
10. Kinsey D, Walther R, Sise HS, Whitelaw GP, Smithwick RH. Incidence of hyperuricaemia in 400 hypertensive subjects. Circulation 1961;24:972-3.
11. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 2011;63:102-10.
12. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 2010;170:1358-64.
13. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009;61:885-92.
14. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 2010;62:170-80.
15. TreeAge Pro 2013 Suite. 1.0.2 ed: TreeAge Software Inc.; 2013.
16. Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011;63:412-21.
17. Arias E. United States life tables, 2008. Natl Vital Stat Rep 2012;61:1-64.
18. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. AHA Statistical Update. Heart disease and stroke statistics-2013 update. Circulation 2013;127:e6-e245.
19. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality - The NHANES I epidemiologic follow-up study 1971-1992. JAMA 2000;283:2404-10.
20. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999;131:7-13.
21. Shurin SB. Morbidity and mortality: 2012 chart book on cardiovascular, lung, and blood diseases. US National Institutes of Health: National Heart, Lung, and Blood Institute. 2012. [Internet. Accessed January 13, 2014.] Available from: www.nhlbi.nih.gov/resources/docs/2012-ChartBook-508.pdf
22. Bhole V, Vera M, Rahman MM, Krishnan E, Choi H. Epidemiology of gout in women. Arthritis Rheum 2010;62:1069-76.
23. Zhu Y, Pandya B, Choi H. Higher serum urate levels correlate with increased prevalence of comorbidities in the US general population: NHANES 1999-2008. Arthritis Rheum 2010;62 Suppl 10:S642.
24. Alper AB Jr., Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood uric acid predicts adult blood pressure: The Bogalusa Heart Study. Hypertension 2005;45:34-8.
25. Dyer AR, Liu K, Walsh M, Kiefe C, Jacobs DR Jr., Bild DE. Ten-year incidence of elevated blood pressure and its predictors: The CARDIA study. Coronary Artery Risk Development in (Young) Adults. J Hum Hypertens 1999;13:13-21.
26. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007; 18:287-92.
27. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007;49:298-303.
28. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, et al. Uric acid and the development of hypertension: The normative aging study. Hypertension 2006;48:1031-6.
29. Shankar A, Klein R, Klein BE, Nieto FJ. The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study. J Hum Hypertens 2006;20:937-45.
30. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008;300:924-32.
31. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: The Rotterdam study. Stroke 2006;37:1503-7.
32. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
33. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900.
34. Schretlen DJ, Inscore AB, Vannorsdall TD, Kraut M, Pearlson GD, Gordon B, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007;69:1418-23.
35. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000; 10:136-43.
36. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997;78:147-53.
37. Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology 2013;52:34-44.
38. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99.
39. Mayor S. Cochrane review questions evidence for statins for primary prevention in low risk groups. BMJ 2011;342:d480.
40. Newman D. Statin drugs given for 5 years for heart disease prevention (without known heart disease). [Internet. Accessed January 13, 2014.] Available from: www.thennt.com/nnt/statins-for-heart-disease-prevention-without-prior- heart-disease/
41. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-7.